Cantor Fitzgerald initiated coverage of Legend Biotech with an Overweight rating and $82 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech Boosts Drug Production with Novartis
- Legend Biotech files automatic mixed securities shelf
- Legend Biotech price target raised to $81 from $76 at UBS
- Legend Biotech notes ODAC recommends Carvykti for earlier treatment of myeloma
- Legend Biotech initiated with an Outperform at Raymond James
Questions or Comments about the article? Write to editor@tipranks.com